Repository logo
 
Publication

Biological activities evaluation of enantiopure isoxazolidine derivatives: in vitro, in vivo and in silico studies

dc.contributor.authorMosbah, Habib
dc.contributor.authorChahdoura, Hassiba
dc.contributor.authorMannai, Asma
dc.contributor.authorSnoussi, Mejdi
dc.contributor.authorAouadi, Kaïss
dc.contributor.authorAbreu, Rui M.V.
dc.contributor.authorBouslama, Ali
dc.contributor.authorAchour, Lotfi
dc.contributor.authorSelmi, Boulbaba
dc.date.accessioned2018-02-19T10:00:00Z
dc.date.accessioned2019-01-28T11:57:09Z
dc.date.available2018-01-19T10:00:00Z
dc.date.available2019-01-28T11:57:09Z
dc.date.issued2019
dc.description.abstractA series of enantiopure isoxazolidines (3a–c) were synthesized by 1,3-dipolar cycloaddition between a (−)-menthone-derived nitrone and various terminal alkenes. The screened compounds were evaluated for their antioxidant activity by two in vitro antioxidant assays, including β-carotene/linoleic acid bleaching, and inhibition of lipid peroxidation (thiobarbituric acid reactive species, TBARS). The results revealed that compound 3b (EC50 = 0.55 ± 0.09 mM) was the most potent antioxidant as compared to the standard drug (EC50 = 2.73 ± 0.07 mM) using the TBARS assay. Furthermore, the antimicrobial activity was assessed using disc diffusion and microdilution methods. Among the synthesized compounds, 3c was found to be the most potent antimicrobial agent as compared to the standard drug. Subsequently, the acute toxicity study has also been carried out for the newly synthesized compounds and the experimental studies revealed that all compounds were safe up to 500 mg/kg and no death of animals were recorded. The cytotoxicity of these compounds was assessed by the MTT cell proliferation assay against the continuous human cell lines HeLa and compound 3c (GI50 = 46.2 ± 1.2 μM) appeared to be more active than compound 3a (GI50 = 200 ± 2.8 μM) and 3b (GI50 = 1400 ± 7.8 μM). Interestingly, all tested compounds displayed a good α-amylase inhibitory activity in competitive manner with IC50 values ranging between 23.7 and 64.35 μM when compared to the standard drug acarbose (IC50 = 282.12 μM). In addition, molecular docking studies were performed to understand the possible binding and the interaction of the most active compounds to the α-amylase pocket.
dc.description.versioninfo:eu-repo/semantics/publishedVersionen_EN
dc.identifier.citationMosbah, Habib; Chahdoura, Hassiba; Mannai, Asma; Snoussi, Mejdi; Aouadi, Kaïss; Abreu, Rui M.V.; Bouslama, Ali; Achour, Lotfi; Selmi, Boulbaba (2019). Biological activities evaluation of enantiopure isoxazolidine derivatives: in vitro, in vivo and in silico studies. Applied Biochemistry and Biotechnology. ISSN 0273-2289. 187:3, p. 1113–1130en_EN
dc.identifier.doi10.1007/s12010-018-2868-2en_EN
dc.identifier.issn0273-2289
dc.identifier.urihttp://hdl.handle.net/10198/18590
dc.language.isoeng
dc.peerreviewedyesen_EN
dc.subjectAcute toxicityen_EN
dc.subjectAntimicrobial activityen_EN
dc.subjectAntioxidant activityen_EN
dc.subjectCytotoxicityen_EN
dc.subjectEnantiopure isoxazolidinesen_EN
dc.subjectMolecular dockingen_EN
dc.subjectα-Amylase inhibitionen_EN
dc.titleBiological activities evaluation of enantiopure isoxazolidine derivatives: in vitro, in vivo and in silico studiesen_EN
dc.typejournal article
dspace.entity.typePublication
person.familyNameAbreu
person.givenNameRui M.V.
person.identifier.ciencia-id0F19-0DE2-12A2
person.identifier.orcid0000-0002-7745-8015
person.identifier.scopus-author-id7003290613
rcaap.rightsopenAccessen_EN
rcaap.typearticleen_EN
relation.isAuthorOfPublicationcadb03a4-5e60-4745-b35f-fc3a97c071bc
relation.isAuthorOfPublication.latestForDiscoverycadb03a4-5e60-4745-b35f-fc3a97c071bc

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
165.pdf
Size:
866.72 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.75 KB
Format:
Plain Text
Description: